WallStreetZenWallStreetZen

NASDAQ: PRME
Prime Medicine Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for PRME

Based on 3 analysts offering 12 month price targets for Prime Medicine Inc

Min Forecast
$4.25+16.44%
Avg Forecast
$8.08+121.45%
Max Forecast
$11.00+201.37%

Should I buy or sell PRME stock?

Based on 3 analysts offering ratings for Prime Medicine Inc.

Buy
Strong Buy
1 analysts 33.33%
Buy
1 analysts 33.33%
Hold
1 analysts 33.33%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although PRME's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates PRME as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their PRME stock forecasts and price targets.

PRME stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-03-12
lockedlocked$00.00+00.00%2025-12-23
lockedlocked$00.00+00.00%2025-11-11
lockedlocked$00.00+00.00%2025-11-10

1 of 1

Forecast return on equity

Is PRME forecast to generate an efficient return?

Company
-116.56%
Industry
66.72%
Market
181.06%
PRME's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is PRME forecast to generate an efficient return on assets?

Company
-41.11%
Industry
32.08%
PRME is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

PRME earnings per share forecast

What is PRME's earnings per share in the next 3 years based on estimates from 14 analysts?

Avg 1 year Forecast
-$0.96
Avg 2 year Forecast
-$0.89
Avg 3 year Forecast
-$0.87

PRME revenue forecast

What is PRME's revenue in the next 3 years based on estimates from 11 analysts?

Avg 1 year Forecast
$5.3M+15.2%
Avg 2 year Forecast
$22.2M+379.49%
Avg 3 year Forecast
$2.4M-49.14%
PRME's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

PRME revenue growth forecast

How is PRME forecast to perform vs Biotechnology companies and vs the US market?

Company
28.42%
Industry
37.55%
Market
13.46%
PRME's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
PRME's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

PRME vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
PRME$3.65$8.08+121.45%Buy
MDXG$4.38$9.50+116.89%Strong Buy
LBRX$25.67$49.00+90.88%Strong Buy
PROK$2.25$12.00+433.33%Buy
ANNX$5.66$20.00+253.36%Strong Buy
View Top Biotech Stocks

Prime Medicine Stock Forecast FAQ

Is Prime Medicine Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: PRME) stock is to Buy PRME stock.

Out of 3 analysts, 1 (33.33%) are recommending PRME as a Strong Buy, 1 (33.33%) are recommending PRME as a Buy, 1 (33.33%) are recommending PRME as a Hold, 0 (0%) are recommending PRME as a Sell, and 0 (0%) are recommending PRME as a Strong Sell.

If you're new to stock investing, here's how to buy Prime Medicine stock.

What is PRME's earnings growth forecast for 2026-2028?

(NASDAQ: PRME) Prime Medicine's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 36.33%.

Prime Medicine's earnings in 2026 is -$201,142,000.On average, 14 Wall Street analysts forecast PRME's earnings for 2026 to be -$172,589,828, with the lowest PRME earnings forecast at -$245,948,178, and the highest PRME earnings forecast at -$106,164,681. On average, 13 Wall Street analysts forecast PRME's earnings for 2027 to be -$161,413,648, with the lowest PRME earnings forecast at -$247,717,590, and the highest PRME earnings forecast at -$66,352,926.

In 2028, PRME is forecast to generate -$156,538,739 in earnings, with the lowest earnings forecast at -$207,021,128 and the highest earnings forecast at -$121,331,064.

What is PRME's revenue growth forecast for 2026-2028?

(NASDAQ: PRME) Prime Medicine's forecast annual revenue growth rate of 28.42% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.55%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.46%.

Prime Medicine's revenue in 2026 is $4,632,000.On average, 11 Wall Street analysts forecast PRME's revenue for 2026 to be $963,426,427, with the lowest PRME revenue forecast at $0, and the highest PRME revenue forecast at $1,895,797,880. On average, 10 Wall Street analysts forecast PRME's revenue for 2027 to be $4,010,063,896, with the lowest PRME revenue forecast at $0, and the highest PRME revenue forecast at $25,593,271,373.

In 2028, PRME is forecast to generate $425,380,934 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $1,668,302,134.

What is PRME's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: PRME) forecast ROA is -41.11%, which is lower than the forecast US Biotechnology industry average of 32.08%.

What is PRME's Price Target?

According to 3 Wall Street analysts that have issued a 1 year PRME price target, the average PRME price target is $8.08, with the highest PRME stock price forecast at $11.00 and the lowest PRME stock price forecast at $4.25.

On average, Wall Street analysts predict that Prime Medicine's share price could reach $8.08 by Mar 12, 2027. The average Prime Medicine stock price prediction forecasts a potential upside of 121.45% from the current PRME share price of $3.65.

What is PRME's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: PRME) Prime Medicine's current Earnings Per Share (EPS) is -$1.35. On average, analysts forecast that PRME's EPS will be -$0.96 for 2026, with the lowest EPS forecast at -$1.36, and the highest EPS forecast at -$0.59. On average, analysts forecast that PRME's EPS will be -$0.89 for 2027, with the lowest EPS forecast at -$1.37, and the highest EPS forecast at -$0.37. In 2028, PRME's EPS is forecast to hit -$0.87 (min: -$1.15, max: -$0.67).

What is PRME's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: PRME) forecast ROE is -116.56%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.